Guggenheim resumed coverage on Amgen with a new price target
$AMGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2025 | $288.00 | Neutral | Guggenheim |
| 4/22/2025 | $305.00 | Neutral | Cantor Fitzgerald |
| 12/10/2024 | $256.00 | Underperform | BofA Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/14/2024 | $335.00 | Neutral | Citigroup |
| 10/17/2024 | $380.00 | Outperform | Bernstein |
| 10/14/2024 | $320.00 → $333.00 | Buy → Hold | Truist |
| 9/27/2024 | $405.00 | Overweight | Cantor Fitzgerald |
Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00
Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00
BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:
Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
4 - AMGEN INC (0000318154) (Reporting)